• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial Clinical Sciences
Conclusions— In patients with systolic HF and sinus rhythm, LVEF is inversely associated with death and its components, whereas an association with stroke exists for very low LVEF values. An interaction with warfarin treatment on stroke risk may exist. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Di Tullio, M. R., Qian, M., Thompson, J. L. P., Labovitz, A. J., Mann, D. L., Sacco, R. L., Pullicino, P. M., Freudenberger, R. S., Teerlink, J. R., Graham, S., Lip, G. Y. H., Levin, B., Mohr, J. P., Buchsbaum, R., Estol, C. J., Lok, D. J., Ponikowski, P. Tags: Heart Failure, Echocardiography, Anticoagulants, Ischemic Stroke Clinical Sciences Source Type: research

Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study Clinical Sciences
Conclusions— AF is more common than present guidelines suggest. The attributable risk of AF for ischemic stroke increases with age and is close to that of hypertension in individuals aged ≥80 years. Because a majority of patients with AF with increased risk for stroke had not received anticoagulation therapy, there is a large potential for improvement.
Source: Stroke - October 21, 2013 Category: Neurology Authors: Bjorck, S., Palaszewski, B., Friberg, L., Bergfeldt, L. Tags: Cerebrovascular disease/stroke, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs, Epidemiology Clinical Sciences Source Type: research

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—Results from our study of the 3 NOACs versus warfarin in nonvalvular atrial fibrillation patients with a previous history of stroke/transient ischemic attack are relatively consistent with their respective phase III trials and previous stroke/transient ischemic attack subgroup analyses. All NOACs seemed no worse than warfarin in respect to ischemic stroke, ICH, or major bleeding risk.
Source: Stroke - July 24, 2017 Category: Neurology Authors: Craig I. Coleman, W. Frank Peacock, Thomas J. Bunz, Mark J. Alberts Tags: Arrhythmias, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke Basic Sciences
Conclusions—In addition to its benefits in infarct size reduction, 12/15-LOX inhibition also may independently reduce HT in warfarin-treated mice. ML351 should be further evaluated as stroke treatment in anticoagulated patients suffering a stroke, either alone or in conjunction with tissue-type plasminogen activator.
Source: Stroke - January 22, 2017 Category: Neurology Authors: Yu Liu, Yi Zheng, Hulya Karatas, Xiaoying Wang, Christian Foerch, Eng H. Lo, Klaus van Leyen Tags: Blood-Brain Barrier, Ischemic Stroke, Neuroprotectants Original Contributions Source Type: research

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin Clinical Sciences
Conclusions—In anticoagulated patients with atrial fibrillation and risk factors for stroke, echocardiographic findings do not seem to add to the risk of thromboembolic events.Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Dragos Vinereanu, Renato D. Lopes, Hillary Mulder, Bernard J. Gersh, Michael Hanna, Pedro G.M. de Barros e Silva, Dan Atar, Lars Wallentin, Christopher B. Granger, John H. Alexander Tags: Arrhythmias, Echocardiography, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Risk Profile of Symptomatic Lacunar Stroke Versus Nonlobar Intracerebral Hemorrhage Brief Reports
Conclusions— The risk factor profile of dICH differs from that associated with LS. This might be used for disease risk stratification at individual level.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Morotti, A., Paciaroni, M., Zini, A., Silvestrelli, G., Del Zotto, E., Caso, V., DellAcqua, M. L., Simone, A. M., Lanari, A., Costa, P., Poli, L., De Giuli, V., Gamba, M., Ciccone, A., Ritelli, M., Di Castelnuovo, A., Iacoviello, L., Colombi, M., Agnelli, Tags: Intracranial Hemorrhage, Ischemic Stroke Brief Reports Source Type: research

Cerebrovascular Accidents During Mechanical Circulatory Support Clinical Sciences
Conclusions—Stroke is a major cause of morbidity and mortality in patients on LVAD support. Chronic obstructive pulmonary disease increases the risk of ischemic stroke, whereas dialysis may increase the risk of hemorrhagic stroke. Although any stroke increases mortality, post-LVAD hemorrhagic stroke was associated with higher mortality compared with ischemic stroke.
Source: Stroke - April 23, 2018 Category: Neurology Authors: Saef Izzy, Daniel B. Rubin, Firas S. Ahmed, Feras Akbik, Simone Renault, Katelyn W. Sylvester, Henrikas Vaitkevicius, Jennifer A. Smallwood, Michael M. Givertz, Steven K. Feske Tags: Heart Failure, Complications, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study Clinical Sciences
Conclusions— In this Asian atrial fibrillation cohort, the mCHA2DS2-VASc score performed better than the CHA2DS2-VASc and would further identify atrial fibrillation patients who may derive a positive net clinical benefit from oral anticoagulation.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Chao, T.-F., Lip, G. Y. H., Liu, C.-J., Tuan, T.-C., Chen, S.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Chen, T.-J., Chiang, C.-E., Chen, S.-A. Tags: Atrial Fibrillation Clinical Sciences Source Type: research

Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control Clinical Sciences
Conclusions— In Chinese patients with atrial fibrillation, the benefits of warfarin therapy for stroke prevention and ICH risk are closely dependent on the quality of anticoagulation, as reflected by TTR. Even at the top TTR quartile, warfarin was associated with a higher stroke and ICH risk than dabigatran.
Source: Stroke - December 22, 2014 Category: Neurology Authors: Ho, C.-W., Ho, M.-H., Chan, P.-H., Hai, J.-J., Cheung, E., Yeung, C.-Y., Lau, K.-K., Chan, K.-H., Lau, C.-P., Lip, G. Y. H., Leung, G. K.-K., Tse, H.-F., Siu, C.-W. Tags: Coumarins, Other anticoagulants, Anticoagulants Clinical Sciences Source Type: research

Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation: Comparison Between Patients With Versus Without Stroke Clinical Sciences
Conclusions— Patients enrolled in RCTs are partly representative of patients with AF in clinical practice. When time in therapeutic range and bleeding tendency with warfarin use were considered, the use of new oral anticoagulants was preferred in patients with stroke than in nonstroke patients, but they were more likely to be excluded in RCTs.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Yoon, C. H., Park, Y. K., Kim, S. J., Lee, M.-j., Ryoo, S., Kim, G.-M., Chung, C.-S., Lee, K. H., Kim, J. S., Bang, O. Y. Tags: Other anticoagulants Clinical Sciences Source Type: research

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients. Major bleeding risk was significantly higher with rivaroxaban than with dabigatran, as was all-cause mortality and gastrointestinal bleeding. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in gastrointestinal bleeding and decreased risk of intracranial hemorrhage.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Ying Bai, Hai Deng, Alena Shantsila, Gregory Y.H. Lip Tags: Meta Analysis, Quality and Outcomes Original Contributions Source Type: research

Dabigatran Versus Warfarin: Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation Clinical Sciences
Conclusions— Hemorrhagic stroke rates were higher on warfarin in Asians versus non-Asians, despite similar blood pressure, younger age, and lower international normalized ratio values. Hemorrhagic strokes were significantly reduced by DE in both Asians and non-Asians. DE benefits were consistent across Asian and non-Asian subgroups. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00262600.
Source: Stroke - June 24, 2013 Category: Neurology Authors: Hori, M., Connolly, S. J., Zhu, J., Liu, L. S., Lau, C.-P., Pais, P., Xavier, D., Kim, S. S., Omar, R., Dans, A. L., Tan, R. S., Chen, J.-H., Tanomsup, S., Watanabe, M., Koyanagi, M., Ezekowitz, M. D., Reilly, P. A., Wallentin, L., Yusuf, S., the RE-LY In Tags: Other anticoagulants, Embolic stroke Clinical Sciences Source Type: research

Warfarin-Associated Intracerebral Hemorrhage After Ischemic Stroke Brief Reports
Conclusions— In this nationwide study, the risk of warfarin-associated ICH among ischemic stroke patients was low and did not change during the 2000s.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Asberg, S., Eriksson, M., Henriksson, K. M., Terent, A. Tags: Intracerebral Hemorrhage, Anticoagulants, Epidemiology Brief Reports Source Type: research

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) Clinical Sciences
Conclusions— Patients with atrial fibrillation with previous IS/TIA are at high risk of recurrent thromboembolism and bleeding. HDER is at least as effective and is safer than warfarin, regardless of the presence or the absence of previous IS or TIA. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Rost, N. S., Giugliano, R. P., Ruff, C. T., Murphy, S. A., Crompton, A. E., Norden, A. D., Silverman, S., Singhal, A. B., Nicolau, J. C., SomaRaju, B., Mercuri, M. F., Antman, E. M., Braunwald, E., on behalf of the ENGAGE AF-TIMI 48 Investigators Tags: Atrial Fibrillation, Anticoagulants, Ischemic Stroke Clinical Sciences Source Type: research

Warfarin Use in Patients With Atrial Fibrillation Undergoing Hemodialysis Clinical Sciences
Conclusions—Our findings suggest that warfarin should be used carefully in hemodialysis patients, given the higher risk of hemorrhagic events and the lack of ability to prevent thromboembolic complications.
Source: Stroke - August 28, 2017 Category: Neurology Authors: Chang-Yun Yoon, Juhwan Noh, Jong Hyun Jhee, Tae Ik Chang, Ea Wha Kang, Youn Kyung Kee, Hyoungnae Kim, Seohyun Park, Hae-Ryong Yun, Su-Young Jung, Hyung Jung Oh, Jung Tak Park, Seung Hyeok Han, Shin-Wook Kang, Changsoo Kim, Tae-Hyun Yoo Tags: Arrhythmias, Clinical Studies, Nephrology and Kidney, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Pages: 1  2  3